What are the indications, insertion procedure, side effects, and alternatives for Mirena (levonorgestrel‑releasing intrauterine system) as a long‑acting reversible contraceptive?

Mirena Birth Control: Comprehensive Clinical Guide

Mirena (levonorgestrel-releasing intrauterine system) is a highly effective long-acting reversible contraceptive with a failure rate of 0.1% that provides contraception for 5 years (FDA-approved) and up to 8 years based on recent evidence, while also offering therapeutic benefits for heavy menstrual bleeding and other gynecologic conditions. 1, 2

Indications

Contraceptive Use

• Primary indication: Long-acting reversible contraception for women of reproductive age, including adolescents and nulliparous women 3
• Efficacy: Pearl Index of 0.13-0.18 per 100 women-years, making it one of the most effective contraceptive methods available 4, 5
• Duration: FDA-approved for 5 years, but recent evidence supports safe and effective use up to 8 years 1, 2

Therapeutic (Non-Contraceptive) Indications

• Heavy menstrual bleeding (menorrhagia): Reduces menstrual blood loss by 71-95% 6, 7
• Dysmenorrhea: Significantly reduces painful menstruation 6
• Endometriosis: Decreases dysmenorrhea, pelvic pain, and dyspareunia 6
• Endometrial hyperplasia: Most women experience disease regression with LNG-IUD use 6
• Adenomyosis and uterine fibroids: Improves hemoglobin levels and reduces bleeding 6

Medical Eligibility

Appropriate Candidates (US MEC Category 1-2)

The LNG-IUD is suitable for most women, including those with 6, 1:

• Nulliparous women and adolescents
• Breastfeeding women (does not negatively affect lactation) 1
• History of ectopic pregnancy
• Past pelvic inflammatory disease (with subsequent pregnancy)
• HIV infection (not immunosuppressed)
• Most cardiovascular conditions
• Diabetes, epilepsy, and most chronic medical conditions

Contraindications (US MEC Category 4)

Do not insert Mirena if the patient has 1, 6:

• Current breast cancer
• Distorted uterine cavity incompatible with IUD insertion
• Current pelvic inflammatory disease
• Purulent cervicitis, current gonorrhea or chlamydia
• Puerperal sepsis or post-septic abortion
• Unexplained vaginal bleeding (before evaluation)
• Malignant gestational trophoblastic disease
• Current cervical or endometrial cancer
• Pelvic tuberculosis

Special Populations Requiring Caution (US MEC Category 3)

• Systemic lupus erythematosus with positive antiphospholipid antibodies 6
• Severe thrombocytopenia (assess bleeding risk) 6
• Past breast cancer without evidence of disease for <5 years 6
• Advanced HIV disease (defer until immune status improves) 8

Insertion Procedure

Timing of Insertion

Optimal timing varies by clinical context 9:

• Mid-cycle (days 10-14): Associated with significantly less pain (VAS 3.1 vs 5.8), less bleeding, and reduced need for analgesia compared to menstrual insertion 9
• During menses (days 3-7): Traditional timing, ensures non-pregnancy but associated with more discomfort 4
• Any time in menstrual cycle: Acceptable if reasonably certain patient is not pregnant 10

Immediate Postpartum Insertion

For high-risk women, immediate postpartum insertion is recommended over delayed placement 1:

• Can be inserted within 10 minutes after placental delivery (vaginal or cesarean)
• Expulsion rate: ~10% with immediate insertion vs. 2% with delayed insertion
• However, 6-month continuation rates are higher with immediate insertion (80% vs. 50%) due to reduced access barriers 1
• Breastfeeding is not affected 1
• Standard recommendation: wait 6 weeks postpartum per prescribing information, but immediate insertion may be considered 4

Pre-Insertion Requirements

Essential assessments (Class A) 10:

• Confirm pregnancy status (use checklist criteria, not necessarily urine test)
• Blood pressure measurement
• Bimanual examination and cervical inspection

STI screening approach 3, 6:

• Screen for gonorrhea and chlamydia on day of insertion in asymptomatic patients at risk
• Treatment can be provided afterward without IUD removal if patient improves
• Defer insertion only if active purulent cervicitis or confirmed current STI

Pre-insertion counseling is critical 11:

• Discuss expected bleeding changes: spotting/light bleeding for first 3-6 months
• Explain that ~50% of users experience amenorrhea or oligomenorrhea by 2 years 11
• Set realistic pain expectations and discuss pain management options 12

Pain Management During Insertion

Recommended multimodal approach 12:

Pre-procedural (offer to all patients):

• NSAIDs: Naproxen or ketorolac 30-60 minutes before insertion
• Anxiolytics: For patients with significant anxiety

Intraprocedural:

• Topical anesthesia application
• Paracervical or intracervical block (most effective pharmacologic intervention)
• Use appropriately sized instruments
• Ensure gradual, gentle technique

Non-pharmacologic interventions:

• Trauma-informed, person-centered care model
• Therapeutic language and comforting environment
• Mind-body techniques to reduce anxiety
• Trained clinical support staff to monitor patient comfort

Side Effects and Management

Expected Bleeding Changes

First 3-6 months 11:

• Unscheduled spotting or light bleeding is expected and generally not harmful
• Decreases with continued use
• Heavy or prolonged bleeding is uncommon

Long-term pattern 11:

• Bleeding generally decreases over time
• Many women experience only light menstrual bleeding or amenorrhea
• Approximately 50% experience amenorrhea by 2 years

Management of Bleeding Irregularities

If irregular bleeding occurs 11:

1. Rule out underlying problems if clinically indicated:

   • LNG-IUD displacement
   • STI or pregnancy
   • New pathologic uterine conditions (polyps, fibroids)

2. For persistent unacceptable bleeding:

   • Treatment options: NSAIDs for 5-7 days (may repeat as needed) 13
   • If bleeding persists despite treatment, counsel on alternative methods

3. For amenorrhea:

   • Provide reassurance—no medical treatment needed
   • If regular pattern changes abruptly to amenorrhea, consider ruling out pregnancy
   • If unacceptable to patient, offer alternative contraceptive methods

Other Common Side Effects 4, 5

• Headaches
• Nausea
• Breast tenderness
• Hair loss (mild, transient)
• Depression or decreased libido
• Ovarian cysts (usually resolve spontaneously)
• Most androgenic effects are mild and resolve after first few months 5

Serious Complications (Rare)

Expulsion: 0-20% depending on patient factors; higher with uterine fibroids (11% vs. 0-3%) 6

Perforation: <2% 1

Pelvic Inflammatory Disease: Risk exists only during first 21 days after insertion 3, 8

Ectopic pregnancy: Absolute number is low; if pregnancy occurs with IUD in place, ectopic must be ruled out 14

Management of Complications

If PID Develops with IUD in Place 11, 6

Do not remove IUD immediately 11:

1. Treat PID according to CDC STD Treatment Guidelines
2. Provide comprehensive management including condom counseling
3. Reassess patient in 24-48 hours
4. If no clinical improvement, continue antibiotics and consider IUD removal
5. If patient desires discontinuation, remove IUD after antibiotics started

Evidence: Treatment outcomes do not differ between women who retain vs. remove IUD, provided appropriate antibiotics and close follow-up occur 11

If Pregnancy Occurs

• Remove IUD if feasible 4
• If strings not visible, ultrasound guidance may be needed
• Counsel on increased risk of complications if IUD remains

Alternatives to Mirena

Other Long-Acting Reversible Contraceptives 1, 3

Levonorgestrel IUDs:

• Liletta: 52 mg levonorgestrel, FDA-approved for 5 years (failure rate 0.1%)
• Kyleena: 19.5 mg levonorgestrel, FDA-approved for 5 years (failure rate 0.1%)
• Skyla: 13.5 mg levonorgestrel, FDA-approved for 3 years (failure rate 0.1%)

Copper IUD:

• Paragard: Copper T380A, FDA-approved for 10 years (failure rate 0.8%)
• Advantage: hormone-free option
• Disadvantage: may increase menstrual bleeding and cramping 6, 8

Contraceptive Implant:

• Nexplanon: Etonogestrel 68 mg, FDA-approved for 3 years (failure rate 0.2%)
• Single-rod subdermal implant inserted in upper arm
• Main side effect: unpredictable bleeding 3

Drug Interactions

Important consideration for HIV-infected patients 8:

• Efavirenz may decrease efficacy of etonogestrel implants (contraceptive failures reported)
• LNG-IUD remains appropriate option as local mechanism of action minimizes systemic drug interactions
• Copper IUD is another excellent alternative (no hormonal interaction)

Key Clinical Pearls

Counseling is paramount: Satisfaction rates reach 77-94% at 3 years when patients receive proper pre-insertion counseling about expected bleeding changes 5, 15

Amenorrhea is not harmful: Reassure patients that absence of menstruation with LNG-IUD is safe and does not require treatment 11

Fertility returns immediately: Normal menstrual pattern and fertility return soon after removal 14

Consider for high-risk pregnancies: Women with medical comorbidities (cardiac disease, diabetes, lupus, etc.) benefit most from highly effective contraception; immediate postpartum LARC should be offered 1

Past PID is not a contraindication: Only current PID or active STI contraindicates insertion 3, 6

Nulliparity is not a contraindication: IUDs do not cause tubal infertility in nulliparous women 3, 8